Lifeline Biotechnologies Inc (LLBO)

[voo]

Email 17-09-2015

Thank you for contacting us at Cyrcadia Health We are grateful for your interest in our product and appreciate you taking the time to contact us. To answer a few common questions concerning the device and associated software, as of June 30, 2015, we are happy to announce that our 4th round of clinical study is now underway and recruiting at El Camino Hospital in Mountain View, CA. Please see the following link for in-depth information about the study as well to understand who to contact for inquiries: clinicaltrials.gov/Cyrcadia.

Based on the pace and outcome of these studies, Cyrcadia intends on launching the CBR™ System in Asia in 2016. Assuming FDA clearance, we hope to begin marketing the device in the US by early 2017. As such, the Cyrcadia Health CBR™ (Circadian Bio Recorder) is intended to be a sold to primary care physicians, ob/gyns, nurse practitioners, and hospitals where it will then be prescribed to patients as part of every woman’s annual healthcare exam.

Currently, Cyrcadia Health is a private company and as such, does not trade on the public markets. However, if there is a private investment interest, please contact Rob Royea at [phone] or via email at [e-mail]. Lifeline Biotechnologies, Inc. remains a key shareholder of Cyrcadia benefitting from both the development and marketing as performed by Cyrcadia. Any ownership of LLBO does not convey or construe direct ownership of Cyrcadia shares. Instead, Cyrcadia can be considered a holding of LLBO. As such, any and all success in Cyrcadia benefits LLBO and its shareholders. Please direct questions relating to Lifeline in general, to Jim Holmes at [phone] or [e-mail]. To stay informed about progress and availability, we can add you to our mailing list per your instructions. If you have any more questions, feel free to contact us at [e-mail] and thank you again for taking the time to show your interest in Cyrcadia Health

Warm Regards,
The Cyrcadia Health Team